title: [Stages in the improvement of drug therapy at a polyclinic].
abstract: Within 1968-1997 the authors studied the steps of introduction of the achievements of the medical science, technology and pharmacology to therapy of exacerbations and complications of peptic ulcer (PU). The scientific and practical value of endoscopic, histological, biochemical and bacteriological examinations in the improvement of the methods of pharmacotherapy of exacerbations and complications of PU was shown. Three phases of the PU development were indicated by the clinical signs and results of esophagogastroduodenoscopy, target biopsy and histological examinations. These data and available scientific achievements were assumed as a basis for the design of optimal drug combinations and their introduction to the medical practice. The use of such combinations made it possible to prevent relapses and life-threatening complications of the disease in the overwhelming majority of the patients. The best results of the pharmacotherapy were recorded in the years (1988-1997) when the drug combinations began to be used. The combinations provided eradication of Helicobacter pylori in the gastroduodenal mucosa and it was proved that in all the patients with PU and the relapsing lesions in the duodenum and in the overwhelming majority of the patients with gastric ulcer the disease developed at the background of chronic active gastroduodenitis associated with H.pylori. The success of the pharmacotherapy in the patients with PU was due to the use of the rational combinations of antibacterial and antisecretory agents.
authors.affiliation: Federal Gastroenterologic Centre, Ministry of Public Health of the Russian Federation, Republican Clinical Hospital, Moscow.
authors.forename: P Ia
authors.initials: PIa
authors.lastname: Grigor'ev
authors.forename: E P
authors.initials: EP
authors.lastname: Iakovenko
authors.forename: N A
authors.initials: NA
authors.lastname: Agafonova
authors.forename: A S
authors.initials: AS
authors.lastname: Prianishnikova
authors.forename: I P
authors.initials: IP
authors.lastname: Soluianova
authors.forename: P V
authors.initials: PV
authors.lastname: Guliaev
authors.forename: A N
authors.initials: AN
authors.lastname: Poliakov
authors.forename: I N
authors.initials: IN
authors.lastname: Usankova
authors.forename: E V
authors.initials: EV
authors.lastname: Talanova
authors.forename: A V
authors.initials: AV
authors.lastname: Iakovenko
authors.forename: I V
authors.initials: IV
authors.lastname: Vasil'ev
authors.forename: N G
authors.initials: NG
authors.lastname: Rumiantseva
authors.forename: N A
authors.initials: NA
authors.lastname: Slobodkina
mesh_terms: D000553:Ambulatory Care / Q000592:standards*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004358:Drug Therapy / Q000592:standards*; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy; D006801:Humans; D009031:Moscow; D010044:Outpatient Clinics, Hospital; D010437:Peptic Ulcer / Q000188:drug therapy; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents